Fig 1: WSGC@MS inhibits the KEAP1/NRF2 signaling pathway in gastric cancer cells. Note: (A–B) Protein levels of NRF2 and KEAP1 in KATO III and MKN-45 cells across different groups. (C–D) Protein levels of NRF2 in the cytoplasm and nucleus of KATO III and MKN-45 cells across different groups (three independent experiments). (E) mRNA levels of NRF2 target genes in KATO III cells, with heat map colors representing gene expression levels. ∗Indicates p < 0.05, ∗∗indicates p < 0.01, ∗∗∗indicates p < 0.001 between the two groups; all cell experiments were repeated three times. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Fig 2: WSGC@MS downregulates FAM117B, reducing its competition with NRF2 for KEAP1 binding. Note: (A) mRNA levels of NRF2 in KATO III and MKN-45 cells across different groups. (B) NRF2 protein levels in KATO III and MKN-45 cells with FAM117B knockdown or overexpression, treated with or without MG132 (20 μM), detected by Western Blot. (C–D) NRF2 degradation half-life in KATO III and MKN-45 cells across different groups. (E–F) Ubiquitination levels of NRF2 in KATO III and MKN-45 cells across different groups. ∗Indicates p < 0.05, ∗∗Indicates p < 0.01, ∗∗∗Indicates p < 0.001 between the two groups; all cell experiments were repeated three times.
Supplier Page from R&D Systems, a Bio-Techne Brand for Recombinant Human GST-KEAP1 Protein, CF